Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18075969 | 0.86 | CHRM4 (0.39) | CHRM1MAPK1TP53TDP1CHRM2 | |
| SCHEMBL18075980 | 0.86 | CHRM4 (0.41) | CHRM1MAPK1TP53TDP1CHRM2 | |
| SCHEMBL18075955 | 0.84 | CHRM4 (0.46) | CHRM1MAPK1TP53CHRM2CHRM4 | |
| SCHEMBL19965818 | 0.79 | CHRM1 (0.48) | CHRM1MAPK1TP53TDP1SMN1; SMN2 | |
| SCHEMBL18075927 | 0.77 | CHRM4 (0.45) | CHRM1MAPK1CHRM2CHRM4CHRM5 | |
| SCHEMBL18075931 | 0.77 | CHRM4 (0.45) | CHRM1MAPK1CHRM2CHRM4CHRM5 | |
| SCHEMBL18075949 | 0.76 | CHRM4 (0.40) | CHRM1MAPK1CHRM2CHRM4ALDH1A1 | |
| SCHEMBL18075967 | 0.76 | CHRM4 (0.44) | CHRM1MAPK1CHRM2CHRM4L3MBTL1 | |
| SCHEMBL18075923 | 0.75 | CHRM4 (0.43) | CHRM1MAPK1CHRM2CHRM4POLB | |
| SCHEMBL19965821 | 0.75 | CCR5 (0.47) | CHRM1MAPK1TP53TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-10167284-B2 | Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20180072727-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167284-B2 | Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885MAPK1 2319/4885TP53 2027/4885 |
| US-20180072727-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885MAPK1 2281/4885TP53 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.